Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)

Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Cardiovascular Research (Impact Factor: 5.94). 12/2004; 64(3):467-76. DOI: 10.1016/j.cardiores.2004.07.023
Source: PubMed


The human ether-a-go-go-related gene (hERG) encodes the rapid component of the cardiac repolarizing delayed rectifier potassium current, I(Kr). The direct interaction of the commonly used protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM I) with hERG, KvLQT1/minK, and I(Kr) currents was investigated in this study.
hERG and KvLQT1/minK channels were heterologously expressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage clamp technique. In addition, hERG currents in stably transfected human embryonic kidney (HEK 293) cells, native I(Kr) currents and action potentials in isolated guinea pig ventricular cardiomyocytes were recorded using whole-cell patch clamp electrophysiology.
Bisindolylmaleimide I blocked hERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner with IC(50) values of 1.0 and 13.2 muM, respectively. hERG channels were primarily blocked in the open state in a frequency-independent manner. Analysis of the voltage-dependence of block revealed a reduction of inhibition at positive membrane potentials. BIM I caused a shift of -20.3 mV in the voltage-dependence of inactivation. The point mutations tyrosine 652 alanine (Y652A) and phenylalanine 656 alanine (F656A) attenuated hERG current blockade, indicating that BIM I binds to a common drug receptor within the pore region. KvLQT1/minK currents were not significantly altered by BIM I. Finally, 1 muM BIM I reduced native I(Kr) currents by 69.2% and lead to action potential prolongation.
In summary, PKC-independent effects have to be carefully considered when using BIM I as PKC inhibitor in experimental models involving hERG channels and I(Kr) currents.

Download full-text


Available from: Christoph Karle, Sep 18, 2014
    • "Whole-cell patch clamp recordings from HEK 293 cells were carried out using a RK-400 amplifier (Bio-Logic SAS, Claix, France) as reported (Thomas et al., 2004a; Gierten et al., 2008; Schmidt et al., 2012; Seyler et al., 2012). "

    No preview · Article · Jan 2015 · Biophysical Journal
  • Source
    • "We found that 1 lM PMA significantly increased peak resurgent current amplitude (Fig. 1A, B, E) without changing the transient current density (measured with the steady-state inactivation protocol by the À110 to 0 mV voltage step; 289 ± 39 vs. 273 ± 59 pA/pF, Control vs. PMA). PMA treatment augmentation of hNav1.7 resurgent current amplitude was prevented by pretreatment with the PKC antagonists Bis I or chelerythrine at the concentration of 1 lM (Fig. 1) [23] [10]. In addition , 1 lM PMA also significantly shifted the peak voltage, the voltage where peak resurgent current was measured (from À39 mV for control to À33 mV for PMA treated; Suppl. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Resurgent sodium currents likely play a role in modulating neuronal excitability. Here we studied whether protein kinase C (PKC) activation can increase resurgent currents produced by the human sodium channel hNav1.7. We found that a PKC agonist significantly enhanced hNav1.7-mediated resurgent currents and this was prevented by PKC antagonists. The enhancing effects were replicated by two phosphorylation-mimicking mutations and were prevented by a phosphorylation-deficient mutation at a conserved PKC phosphorylation site (Serine 1479). Our results suggest that PKC can increase sodium resurgent currents through phosphorylation of a conserved Serine residue located in the domain III-IV linker of sodium channels.
    Full-text · Article · Sep 2014 · FEBS Letters
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in ryanodine receptor calcium ion-release channels (RyR2) have emerged as important causative players in exercise/stress-induced ventricular arrhythmia leading to sudden cardiac death (SCD). Thus, RyR2 represents an attractive therapeutic target, and a detailed understanding of the mechanistic basis of RyR2 dysfunction at the molecular, cellular and organ level is essential for the development of novel, more effective therapeutic approaches to prevent arrhythmia and SCD. Such advances will translate into a tremendous improvement in the survival and quality of life of SCD-susceptible individuals. In this review, the authors consider how recent knowledge gained from mutation identification, phenotypic manifestation and functional evaluation of RyR2 mutants, are being used to develop novel therapeutic strategies in RyR2-dependent arrhythmia.
    Full-text · Article · Jul 2005 · Future Cardiology
Show more